Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.
about
AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies.Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapyOngoing trials of immune-based therapies for HIV infection in adults.Current progress in the development of a prophylactic vaccine for HIV-1.Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients.Progress on new vaccine strategies against chronic viral infectionsTherapeutic vaccines against HIV infection.New challenges in therapeutic vaccines against HIV infection.NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients.
P2860
Q34047774-D660C646-C971-4253-B7D0-5FB56EFD945CQ34255648-8874251B-62A1-4399-B120-6570B28ED649Q34325840-0A23C4FE-3620-4B6C-83C6-139DF9C2A912Q34332119-106BE9FB-F1E9-4DA2-BC15-8D17DBBF89F2Q34451967-B8592807-D154-4E75-AE02-0F4F48629B21Q34502108-9066A86E-B327-47CD-905B-7E256B865425Q34631665-0FB78A81-CCCD-46AD-8831-132F1C21A3F0Q35864857-5D6A8138-E820-4022-A261-2F6FC35B50C9Q38013505-1F978D26-153C-41C8-B0C7-3053CCD06C87Q38692205-EA5B9076-9222-44DC-BAF2-5E36FC49DC7DQ44766920-76AF6428-8DBF-4C03-AD31-08B8772D6DD6
P2860
Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Two double-blinded, randomized ...... cal Trials Groups 209 and 214.
@en
Two double-blinded, randomized ...... cal Trials Groups 209 and 214.
@nl
type
label
Two double-blinded, randomized ...... cal Trials Groups 209 and 214.
@en
Two double-blinded, randomized ...... cal Trials Groups 209 and 214.
@nl
prefLabel
Two double-blinded, randomized ...... cal Trials Groups 209 and 214.
@en
Two double-blinded, randomized ...... cal Trials Groups 209 and 214.
@nl
P2093
P356
P1476
Two double-blinded, randomized ...... cal Trials Groups 209 and 214.
@en
P2093
Chernoff D
Friedland G
P304
P356
10.1086/315860
P407
P577
2000-10-09T00:00:00Z